Jifeng Feng

Sign up to set email alerts
|
33Publications
18,136Citation Statements Received
827Citation Statements Given
How they've been cited
21,059
705
17,300
131
How they cite others
1,059
49
773
5
Publications
Order By: Most citations

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Cheng
1
,
Kang
2
,
Chen
3
et al. 2009
The Lancet Oncology
5,081
188
4,646
41
View full textAdd to dashboardCite

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou
1
,
Wu
2
,
Chen
3
et al. 2011
The Lancet Oncology
3,530
84
2,373
16
View full textAdd to dashboardCite

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok1,
Wu2,
Kudaba3
et al. 2019
The Lancet
2,378
84
1,885
11
View full textAdd to dashboardCite

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu
1
,
Zhou
2
,
Hu
3
et al. 2014
The Lancet Oncology
1,712
71
1,401
12
View full textAdd to dashboardCite

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Paz‐Ares1,
Dvorkin2,
Chen3
et al. 2019
The Lancet
1,308
23
1,117
3
View full textAdd to dashboardCite

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang
1
,
Wu
2
,
Schüler3
et al. 2015
The Lancet Oncology
1,382
50
1,017
5
View full textAdd to dashboardCite

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

Satoh
1
,
Xu
2
,
Chung
3
et al. 2014
JCO
529
8
382
1
View full textAdd to dashboardCite
show abstract

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

Zhou
1
,
Wu
2
,
Chen
3
et al. 2015
JCO
311
24
295
2
View full textAdd to dashboardCite
show abstract
scite logo

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product
Browser ExtensionAssistant by sciteCitation Statement SearchReference CheckVisualizationsDashboardsExplore JournalsExplore OrganizationsExplore FundersEmbedding BadgeEmbedding Citation SearchPricing
Resources
BlogHelp & FAQAccessibility StatementAPI TermsFor Universities & GovernmentsFor ResearchersFor PublishersFor Corporate, Pharma & EnterpriseAuthor MarketingBecome an AffiliateGet an organization trial or quotescite Data & Services
About
News & PressCareersRead our PaperCoverage

BlogTerms and ConditionsAPI TermsPrivacy PolicyContactCookie PreferencesDo Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.